Pcn215 - Emerging Trends in the Management of NSCLC Pd-L1+ Patients in Italy

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.297
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P073 CBL-B Predicts Prognosis of NSCLC Patients and Affects PD-L1 Expression in A549

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1-Hemmer Bei Vorbehandelten Patienten Mit NSCLC

Im Focus Onkologie
2017English

NSCLC: Zwei Positive Studien Zu PD-L1-Hemmer

Im Focus Onkologie
2015English

NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status

Pneumologie
MedicinePulmonaryRespiratory Medicine
2017English

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy